Today: 7 February 2026
Subscribe

GE Vernova stock jumps 6% on White House push for emergency PJM power auction

GE Vernova stock jumps 6% on White House push for emergency PJM power auction

GE Vernova shares surged 6.1% to $681.55 Friday after U.S. officials urged faster power expansion for data centers, prompting a White House call for PJM Interconnection to hold an emergency auction. Constellation Energy fell 9.8% and Vistra dropped 7.5% on concerns over price caps and new supply. PJM will discuss new power user rules Jan. 22. Markets reopen Tuesday after the holiday.
17 January 2026
···
Yes Bank Q3 profit jumps 55% — provisions slide and CEO flags roadmap, succession

Yes Bank Q3 profit jumps 55% — provisions slide and CEO flags roadmap, succession

Yes Bank reported a Q3 FY26 standalone net profit of 951.6 crore rupees, up from 612 crore a year earlier, as provisions fell to 22 crore. Net interest income rose 10.9% to 2,466 crore, while the gross bad-loan ratio narrowed to 1.5%. CEO Prashant Kumar said a strategic roadmap will be unveiled this quarter and succession planning is underway. Loans grew 5.2% year-on-year to 2.57 trillion rupees.
17 January 2026
····
Adobe stock price ends week at $296: what ADBE traders watch after the long market break

Adobe stock price ends week at $296: what ADBE traders watch after the long market break

Adobe shares fell 2.6% to $296.12 Friday, marking a sixth straight decline as volume nearly doubled its 50-day average. The stock has dropped about 36% from its 52-week high. Chief Marketing Officer Lara Balazs sold 1,976 shares to cover taxes after restricted stock units vested, according to an SEC filing. U.S. markets will be closed Monday for Martin Luther King Jr. Day.
17 January 2026
·
Intuitive Machines stock surges 11% after Morgan Stanley turns upbeat on space — what to watch next week

Intuitive Machines stock surges 11% after Morgan Stanley turns upbeat on space — what to watch next week

Intuitive Machines shares jumped 10.7% Friday to close at $21.58 after news of its $800 million Lanteris acquisition and a bullish Morgan Stanley sector call. Trading volume hit 19.6 million shares. U.S. markets will close Monday for Martin Luther King Jr. Day, with trading set to resume Tuesday. Morgan Stanley also upgraded Rocket Lab and MDA, while downgrading Iridium.
17 January 2026
·····
ZIM stock slides nearly 6% as freight rates cool and Suez route talk returns

ZIM stock slides nearly 6% as freight rates cool and Suez route talk returns

ZIM Integrated Shipping shares fell 5.9% to $21.36 Friday as container freight rates dropped, with Drewry’s World Container Index down 4% to $2,445 per 40-foot box. Maersk and CMA CGM began shifting services back to the Suez Canal, but Germany’s VDA warned of insurance and safety concerns. ZIM’s board is reviewing takeover bids after rejecting a management offer. U.S. markets close Monday for Martin Luther King Jr. Day.
17 January 2026
··
JetBlue stock jumps 8% into long weekend as traders brace for JBLU earnings

JetBlue stock jumps 8% into long weekend as traders brace for JBLU earnings

JetBlue shares surged 8.03% Friday to $5.38, extending gains as major U.S. indexes slipped. Trading volume spiked ahead of the long holiday weekend, with markets closed Monday for Martin Luther King Jr. Day. The FAA warned airlines about risks over parts of Latin America due to military activity and GPS interference. JetBlue will report earnings January 27.
17 January 2026
···
1 … 581 582 583 584 585 … 2,714

Stock Market Today

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

7 February 2026
New York, February 7, 2026, 05:48 EST — Market closed Pfizer Inc (PFE) shares ended Friday up 2.8% at $27.22, after trading between $26.52 and $27.37. About 50.7 million shares changed hands. (Yahoo Finance) The stock’s late-week lift comes with a key regulatory clock running: the FDA granted priority review for Pfizer’s supplemental filing to broaden use of its hemophilia drug Hympavzi, with a target decision deadline in the second quarter. Priority review shortens the agency’s standard review timeline by four months. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,”
Go toTop